About CytokineticsCytokinetics is a biopharmaceutical company focused on the discovery online pharmacy.

About CytokineticsCytokinetics is a biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target concentrated the cytoskeleton online pharmacy . The cytoskeleton is a complex biological infrastructure a key role in every human cell plays. Cytokinetics ‘ focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs in treatments for cancer, cardiovascular disease and other illnesses directed. Established a strategic alliance in 2001, are Cytokinetics and GlaxoSmithKline , in order to develop and commercialize small molecule therapeutics human mitotic kinesin for applications in the treatment of cancer and other diseases. Ispinesib , SB – 743921 and GSK – 923295 under the strategic under the strategic alliance with GSK. GSK is conducting Phase II and Ib clinical trials for ispinesib and a Phase I clinical trial of SB – 743921 and Cytokinetics is a phase I / II trial of SB – 743921 in non-Hodgkin’s lymphoma. Unpartnered Cytokinetics ‘ cardiovascular disease program is to use the second program, the company’s expertise in cytoskeletal pharmacology. Cytokinetics recently completed a Phase I clinical trial of CK – 1827452, A novel small molecule cardiac myosin activator for the intravenous treatment of heart failure and also forward CK as a potential as a potential drug candidate for the treatment of chronic heart failure via oral administration For more information about Cytokinetics can be obtained. This press release contains forward-looking statements within the meaning the Private Securities Litigation Reform Act of 1995 . Cytokinetics disclaims any intent or these these forward-looking statements, and claims the protection of the Safe Harbor contained for forward-looking statements within the law. Not limited to statements include, but are not limited to, statements about the timing, scope and focus of clinical research and development Cytokinetics ‘ activities using respect to CK – 1827452, the size and growth of anticipated markets for CK – 1827452, the potential limited benefits of CK – 1827452, the possibility of new treatment paradigms with CK – 1827452, other drugs other drugs Cytokinetics ‘ candidates and potential drug candidates and the advantages of data from completed clinical trials receive. Such forward-looking statements are based upon current expectations are based, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, the risks or uncertainties relating to difficulties or delays in patient enrollment in clinical trials, unexpected side effects or inadequate therapeutic efficacy of CK – 1827452 and Cytokinetics ‘ other drug candidates and other limited potential difficulties or delays in the development, testing, approval, production and marketing of CK – 1827452 and Cytokinetics ‘ other drug candidates slow or prevent clinical development, approval approval or market acceptance , changing standards of care and the introduction of competing products or alternative therapies for treating indications of currently or potentially targeted by CK – 1827452 and the implementation and maintenance of procedures, policies, resources and infrastructure to meet new or changing laws, regulations and practices. For more information these and other risks related to Cytokinetics filings with the Securities and Exchange Commission business Cytokinetics Cytokinetics investors ‘.

Cytokinetics expects that CK – 1827452 will be entering an international Phase II clinical trials program in heart failure patients in the second half of 2006. This program is planned, CK – 1827452 in a variety of patients, including patients with stable heart failure, to assess inducible ischemia, renal failure and acute heart failure. This program is designed safety and efficacy of safety and efficacy of CK – 1827452, both intravenous and oral formulations, for the potential treatment of heart failure in the continuity of care, both in the hospital setting and in the outpatient area.

Earch the archives , or sign up for email notification on the Emperor Daily Health Policy Report strongly in favor emperor network. A free service from of The Henry J. Publishes. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All Rights Reserved part.